CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 41 enrolled
Drug / intervention
A-101 Topical Solutiondrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03487588
NCT03487588Phase 4Completed

An Open-Label Study Assessing Subject Satisfaction With A-101 Hydrogen Peroxide Topical Solution, 40% (w/w) Treatment for Seborrheic Keratoses of the Face, Neck, and Decolletage

Aclaris Therapeutics, Inc.·interventional·Posted Apr 4, 2018·Updated Oct 2, 2019

In Brief

A Phase 4 clinical trial evaluating A-101 Topical Solution for Seborrheic Keratosis. Completed, enrolled 41 participants across 3 sites.

Detailed Summary

This study is an open-label study designed to evaluate subject's satisfaction after treatment of seborrheic keratoses with A-101 40%.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
201820192020202120222023202420252026
First PostedApr 4, 2018
Enrollment StartMar 21, 2018
Primary CompletionNov 14, 2018
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 8.2 years ago

Interventions

A-101 Topical Solutiondrug

A-101 Topical Solution applied Day 1, Day 15 and Day 29